Expand Your Treatment Focus with the TearCare® System

Get a Closer Look at One of the Most Studied Devices in MGD

Learn More
Press Release July 20, 2023
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
View Press Release
American Academy of Optometry, October 2022, San Diego, CA
TearCare® for the Treatment of Meibomian Gland Dysfunction: A Single-Center Trial Measuring Durability of Treatment

Tom Chester, OD
Tanner Ferguson, MD
Emma Chester

View Poster
Optometry and Vision Science
Author's Accepted Manuscript

Localized Heat Treatment for Meibomian Gland Dysfunction: A Single Center Retrospective Analysis of Efficacy over Time 

Tom Chester, OD
Tanner Ferguson, MD
Emma Chester

View Study Details
Cornea, September 2021
TearCare® for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial

Preeya K. Gupta, MD
Edward J. Holland, MD
John Hovanesian, MD
Jennifer Loh, MD
Mitchell A. Jackson, MD
Paul M. Karpecki, OD
Kavita Dhamdhere, MD, PhD

View Study Details
Clinical Ophthalmology, August 2022
A Comparison of TearCare® and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease

Edward J Holland, MD
Jennifer Loh, MD
Marc Bloomenstein, OD
Vance Thompson, MD
David Wirta, MD
Kavita Dhamdhere, MD, PHD

View Study Details
Clinical Ophthalmology, December 2020
A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease

Paul Karpecki, OD
David Wirta, MD
Smajo Osmanovic, MD
Kavita Dhamdhere, MD, PhD

View Study Details
Optometry and Vision Science, June 2021
A Single-center Retrospective Trial of a Blink-assisted Eyelid Device in Treating the Signs and Symptoms of Dry Eye
Thomas Chester, OD
View Study Details
Clinical Ophthalmology, January 2019
TearCare® System Extension Study: Evaluation of the Safety, Effectiveness, and Durability Through 12 Months of a Second TearCare® Treatment on Subjects with Dry Eye Disease
David Badawi, MD
View Study Details
Clinical Ophthalmology, April 2018
A Novel System, TearCare®, for the Treatment of the Signs and Symptoms of Dry Eye Disease
David Badawi, MD
View Study Details

Learn more about the TearCare® System

    Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
    T    he TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.

    4040 Campbell Ave, Suite 100
    Menlo Park CA 94025
    T: 877-266-1144
    E: tearcare@sightsciences.com

    © 2023 Sight Sciences, Inc.     7/23     TC-1697-US.v3 Privacy Policy Cookie Policy 
    TearCare®, SmartLids™, SmartHub™, Clearance Assistant™, Sight Sciences, and the Sight Sciences logo are trademarks or registered trademarks of Sight Sciences.